Filing Flows › Royalty Pharma (RPRX) › Q3 2026 › vs Q3 2025
Royalty Pharma (RPRX) Q3 2026 vs Q3 2025 (year over year)
Royalty Pharma's revenue rose $80.8M (+13%) from $609M in Q3 2025 to $690M in Q3 2026. The biggest changes: Income from financial royalty assets +$68.8M (+12%); Other royalty income and revenues +$12.0M (+39%). Operating margin 59.5% against 70.1% (-10.6 pts).
Royalty Pharma, Q3 2026: revenue $690M (+13% year over year), operating margin 59.5%, net earnings $145M, operating cash flow $686M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 59.5% | 70.1% | -10.6 pts |
| Net margin | 21.0% | 46.6% | -25.7 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Income from financial royalty assets | $648M | $579M | $68.8M | +12% |
| Other royalty income and revenues | $42.5M | $30.5M | $12.0M | +39% |
| Revenue | $690M | $609M | $80.8M | +13% |
| Operating profit | $411M | $427M | −$16.3M | -4% |
| Costs & expenses | $279M | $182M | $97.1M | +53% |
| Pre-tax earnings | $267M | $440M | −$174M | -39% |
| Other expense, net | $144M | −$13.1M | $157M | — |
| Research & development | $63.2M | $50.5M | $12.7M | +25% |
| General & admin | $150M | $119M | $31.4M | +26% |
| Other operating costs | $66.0M | $12.9M | $53.1M | +412% |
| Net earnings | $145M | $284M | −$140M | -49% |
| Minority interests | $122M | $156M | −$34.0M | -22% |
| Depreciation | $1.2M | $1.3M | −$56K | -4% |
| Share-based compensation | $105M | $72.8M | $32.0M | +44% |
| Working capital & other | $435M | $344M | $91.0M | +26% |
| Operating cash flow | $686M | $703M | −$16.5M | -2% |
Questions
How much did Royalty Pharma's revenue grow year over year in Q3 2026?
Royalty Pharma's revenue rose $80.8M (+13%) from $609M in Q3 2025 to $690M in Q3 2026.
What drove Royalty Pharma's revenue change in Q3 2026?
Income from financial royalty assets +$68.8M (+12%); Other royalty income and revenues +$12.0M (+39%).